Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 10,300 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total value of $10,403.00. Following the sale, the insider now directly owns 316,604 shares of the company’s stock, valued at approximately $319,770.04. The trade was a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $48,048.10.

Nektar Therapeutics Price Performance

Shares of NASDAQ NKTR opened at $0.93 on Friday. Nektar Therapeutics has a 12 month low of $0.63 and a 12 month high of $1.93. The stock has a 50-day moving average price of $0.92 and a two-hundred day moving average price of $1.12.

Hedge Funds Weigh In On Nektar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC increased its holdings in shares of Nektar Therapeutics by 56.3% during the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 9,958 shares in the last quarter. Harvest Investment Services LLC bought a new position in Nektar Therapeutics in the fourth quarter valued at about $27,000. US Asset Management LLC bought a new position in Nektar Therapeutics in the fourth quarter valued at about $31,000. Valence8 US LP acquired a new stake in shares of Nektar Therapeutics during the third quarter valued at about $34,000. Finally, Intech Investment Management LLC bought a new stake in shares of Nektar Therapeutics during the third quarter worth about $41,000. Institutional investors own 75.88% of the company’s stock.

Wall Street Analysts Forecast Growth

NKTR has been the topic of several research reports. B. Riley initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price target on the stock. Piper Sandler started coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.